glp-1 receptor agonists and sglt2 inhibitors Complementary Yet Distinct Roles of in Cardiovascular Risk Reduction GLP-1 receptor agonists and SGLT2

Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization

Green tea, gymnema, turmeric, and B vitamins provide antioxidant and metabolic support

Regulatory submission for retatrutide is expected in 2026

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery